Diagnostics

MCRA Supports CamDiab with FDA Approval for Artificial Pancreas Software

WASHINGTON, June 26, 2024 /PRNewswire/ -- MCRA, the leading privately held independent medical device, diagnostics, and biologics Clinical Research Organization…

5 months ago

ZEISS arivis software enhances custom microscopy image analysis

Introducing ZEISS arivis Pro 4.2 Offers users the freedom to select the most suitable image analysis method for their needsNew…

5 months ago

CUNY SPH receives $5.2 million NIH grant renewal for cancer genomics research

NEW YORK, June 25, 2024 /PRNewswire/ -- The Informatics Technology for Cancer Research (ITCR) program of the NIH National Cancer…

5 months ago

Zeto Announces Winners of Clinical Trial Sponsorship Program

SANTA CLARA, Calif., June 25, 2024 /PRNewswire/ -- Zeto, Inc., an award-winning medical technology firm, is proud to announce the…

5 months ago

Prospective Trial Shows Impact of Home OCT Guided Wet AMD Patient Management

Remote monitoring reduces office visit and treatment burden in some patientsManassas, Virginia--(Newsfile Corp. - June 25, 2024) - Digital healthcare…

5 months ago

GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease

Results from commercial sales of predictive testing across the US and Australia establish clear advantages of geneType Risk Assessment Tests…

5 months ago

Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ:…

5 months ago

Insider Information: Nexstim Plc’s offering for an EUR 750,000 convertible bond has closed and EUR 650,000 of the bond was subscribed for

Company Announcement, Helsinki, 25 June 2024 at 9:30 AM (EEST) Insider Information: Nexstim Plc’s offering for an EUR 750,000 convertible…

5 months ago

Insider Information: Nexstim Plc launches an unsecured convertible bond offering of up to EUR 750,000

Company Announcement, Helsinki, 25 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc launches an unsecured convertible bond offering…

5 months ago

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV)…

5 months ago